Welcome to the fourth of five episodes in our podcast series “Digital Deals in Life Sciences – What Makes Them Different?" Transactions involving digital assets are an increasing focus for pharmaceuticals, medical device and medtech companies. In this series, life sciences industry M&A veteran and Sterling Technology board advisor John Easton discusses how these differ from traditional life science deals, and what both acquiror and target should look out for to increase the chances of deal success, mitigate risks, and avoid failure.
Technology targets will likely present challenges to dealmakers who are more comfortable evaluating traditional in-licensing or acquisition transactions with pharmaceutical or biotech companies. How should acquirors successfully conduct due diligence on digital assets and what capabilities do they need? To find out, click below and listen to our latest episode. You can also add the podcast series to one of several apps, such as Apple Podcasts, by clicking the "+ Follow" link.
If you want to listen to the first three episodes, please visit our Insights page. You can also learn more by downloading our report which accompanies this podcast series. 👇
Are you ready for a digital-first future in life sciences? This new report explores the challenges and opportunities presented by digital deals. Essential reading for life sciences dealmakers seeking to navigate an unfamiliar terrain of transactions involving artificial intelligence, machine learning and big data, our report provides insights into differences between digital and traditional deals in key areas including corporate culture, data privacy, intellectual property, asset valuation, due diligence and deal structuring. To receive a copy, please click here to fill in your details in the form at the bottom of the page. 👇
